Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-302)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Robert Keenan, MD
Arthrosi Therapeutics, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
68 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Arthrosi Investigative Site (202)
Botany, New South Wales, Australia
- Arthrosi Investigative Site (200)
Camberwell, Victoria, Australia
- Arthrosi Investigative Site (500)
Hong Kong, Central, Hong Kong
- Arthrosi Investigative Site (501)
Hong Kong, Hong Kong Island, Hong Kong
- Arthrosi Investigative Site (300)
Auckland, Auckland, New Zealand
- Arthrosi Investigative Site (304)
Hamilton, Hamilton, New Zealand
- Arthrosi Investigative Site (302)
Auckland, New Zealand, New Zealand
- Arthrosi Investigative Site (303)
Nelson, New Zealand, New Zealand
- Arthrosi Investigative Site (301)
Rotorua, New Zealand, New Zealand
- Arthrosi Investigative Site (405)
Hualien City, Taiwan, Taiwan
- Arthrosi Investigative Site (404)
Kaohsiung City, Taiwan, Taiwan
- Arthrosi Investigative Site (400)
Taipei, Taiwan, Taiwan
- Arthrosi Investigative Site (403)
Taipei, Taiwan, Taiwan
- Arthrosi Investigative Site (401)
Taoyuan City, Taiwan, Taiwan
- Arthrosi Investigative Site (406)
Kaohsiung City, Taiwan
- Arthrosi Investigative Site (402)
Taichung, Taiwan
- Arthrosi Investigative Site (106)
Foley, Alabama, United States
- Arthrosi Investigative Site (139)
Anchorage, Alaska, United States
- Arthrosi Investigative Site (160)
Peoria, Arizona, United States
- Arthrosi Investigative Site (112)
Phoenix, Arizona, United States
- Arthrosi Investigative Site (114)
Tempe, Arizona, United States
- Arthrosi Investigative Site (131)
El Cajon, California, United States
- Arthrosi Investigative Site (117)
Encinitas, California, United States
- Arthrosi Investigative Site (138)
Rancho Cucamonga, California, United States
- Arthrosi Investigative Site (161)
Valencia, California, United States
- Arthrosi Investigative Site (101)
Aurora, Colorado, United States
- Arthrosi Investigative Site (149)
Clearwater, Florida, United States
- Arthrosi Investigative Site (115)
Coral Gables, Florida, United States
- Arthrosi Investigative Site (128)
DeLand, Florida, United States
- Arthrosi Investigative Site (102)
Hollywood, Florida, United States
- Arthrosi Investigative Site (156)
Maitland, Florida, United States
- Arthrosi Investigative Site (103)
Miami, Florida, United States
- Arthrosi Investigative Site (157)
Palmetto Bay, Florida, United States
- Arthrosi Investigative Site (151)
Winter Haven, Florida, United States
- Arthrosi Investigative Site (164)
Atlanta, Georgia, United States
- Arthrosi Investigative Site (162)
Lilburn, Georgia, United States
- Arthrosi Investigative Site (133)
Boise, Idaho, United States
- Arthrosi Investigative Site (122)
River Forest, Illinois, United States
- Arthrosi Investigative Site (154)
Wichita, Kansas, United States
- Arthrosi Investigative Site (144)
New Orleans, Louisiana, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 26 Jun 2024
- Primary completion
- 20 Mar 2026
- Completion
- 10 Apr 2026
- Last update posted
- 13 May 2026
- Registered enrollment
- 818
- Registry id
- NCT06439602
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.